Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 40

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 40
---
 are no active research and development programs based on our drug delivery technologies.

Additionalinformation regarding the general development of our business is set forth in our Annual Report on Form 20-F for the year ended
December 31, 2024.

| 26 |

Financial Update

As of September 30, 2025,
we had cash and cash equivalents of £2.79 million.

Financial information as of
September 30, 2025 in this prospectus has not been audited and has been prepared by, and is the responsibility of, our management. This
data could change as a result of further review. In addition, our independent registered public accounting firm has not audited, reviewed,
compiled, or performed any procedures with respect to this unaudited financial information and does not express an opinion or any other
form of assurance with respect thereto. Accordingly, you should not place undue reliance on this information. Additional information and
disclosures would be required for a more complete understanding of our financial condition, liquidity, and results of operations as of
September 30, 2025. Complete annual results will be included in our Annual Report on Form 20-F for the year ended December 31, 2025.

Recent Developments

Ratio Change

On July 31, 2025, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share
to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

June 2025 GM

On June 11, 2025, we held
the June 2025 GM and our shareholders passed resolutions to (i) subdivide our Ordinary Shares of £0.00005 nominal value each into
one ordinary share of £0.000001 nominal value and 49 D deferred shares of £0.000001 nominal value each, and (ii) adopt new
Articles of Association, which made consequential amendments to the existing Articles of Association of the Company to reflect the June
Subdivision. As is standard for deferred shares, each D deferred share has very limited rights and is effectively valueless. The D deferred
shares have the rights and restrictions as set out in the Articles of Association and do not entitle the holder thereof to receive notice
of or attend and vote at any general meeting of the Company or to receive a dividend or other distribution.

Warrant Inducement

On May 15, 2025, we